For instance, Affimed Therapeutics has developed a high affinity/selectivity IgG-based anti-CD16a antibody (known as ROCK® platform), which is in Phase I clinical studies for the treatment of lymphomas (NCT04101331) (37). Here, FCGR3A is linked to lymphoma.